Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers Trustpilot target price on revised valuation model

(Sharecast News) - Analysts at Berenberg reduced their target price on reviews website operator Trustpilot from 420p to 300p on Tuesday following the company's interim results. Berenberg said Trustpilot's first-half results showed that it had delivered "strong profitability and cash generation" in the six months ended 30 June, as well as another upgrade to its FY25 adjusted underlying earnings margin guidance.

The German bank stated that Trustpilot had shown that it has made progress across its financial and operational KPIs, as it continues to demonstrate the efficacy of its product offering to larger organisations, with recent enterprise customer wins including Barclays, Boots, Amundi, Lindt and Experian.

As such, Berenberg, which has a 'buy' rating on the stock, upgraded its adjusted EBITDA forecasts by 9% each for FY25, FY26 and FY27, primarily reflecting increased margin expectations," said Berenberg.

Berenberg also highlighted that while it had reduced its price target on the stock, this was a result of "a more prudent valuation methodology", rather than any decline in Trustpilot's business prospects, which it believes "remain strong".

"While we upgrade our adjusted EBITDA estimates by 9% in each of FY25, FY26 and FY27, we also refresh our DCF valuation model, increasing our WACC to 10.9% (previously 8.0%), which we think is a more suitable level for a business of Trustpilot's maturity and risk profile," concluded Berenberg.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.